Industry / Russia
If you would like to subscribe to Emerging Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Emerging Europe Pharma & Healthcare Insight please click on the trial link below.
Veropharm Grows Strongly In H108
August 2008 | Company News AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Emerging Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Emerging Europe Pharma & Healthcare Insight please click on the trial link below.
Russian drugmaker Veropharm is set for another year of record sales after posting sales of US$86.5mn in H108, up 45.4% year-on-year (y-o-y). Driven by a thriving local market and a growing focus on high margin oncology products, the manufacturer also realised a significant increase in earnings before interest, taxes, depreciation and amortization (EBITDA) that was up 67.9% y-o-y to